Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2017-06-09 Capital/Financing Update
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
S-3
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC by TG Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 for the offering of securities including common stock, preferred stock, warrants, debt securities, and units. The document includes a base prospectus and a sales agreement prospectus for an at-the-market offering. The content is focused on securities registration and offering details, not on financial results, management discussion, or other report types. Form S-3 filings are related to capital raising and securities offerings. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Hence, the classification is CAP with high confidence.
2017-06-09 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions the announcement of positive clinical trial results and updated clinical data via press releases, which are included as exhibits. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is primarily an announcement of events and press releases, not a full report or transcript. Given the nature of the filing and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-06-05 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement used by companies to register securities for sale to the public, often as part of a shelf registration allowing multiple offerings over time. The document includes details about the types of securities to be offered, the registration fee, and legal disclaimers. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits best under the category Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration information, not just an announcement or notice, so it is not an RPA or RNS. Confidence is high given the clear identification as a Form S-3 registration statement.
2017-05-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an Item 8.01 'Other Events' describing a press release about a clinical trial interim analysis, and the press release is attached as Exhibit 99.1. The document length is 2870 characters, which is relatively short and mainly serves to announce the event and attach the press release. There are no detailed financial statements or comprehensive financial data presented. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-05-24 English
10-Q
Interim / Quarterly Report Q1 2017
2017-05-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 5, 2017, reporting the results of operations for the first quarter ended March 31, 2017. It mentions a press release announcing the financial results and an upcoming investor conference call. The document itself is short (2518 characters) and primarily serves to announce the release of financial results and the conference call, rather than containing detailed financial statements or substantive financial data. According to the 'MENU VS MEAL' rule, such a short document that announces a report or event is classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR). Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-05-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.